Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

NCT02425683 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped insufficient accrual

Conditions

Colorectal Neoplasms
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum

Interventions

DRUG: Regorafenib

Sponsor

US Oncology Research

Collaborators

[object Object]